Physician profile
Samuel Brady
NPI 1174156699
$1,460.31
in general payments reported to CMS, 2019-2025
11 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,162 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,061 · Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,060.86 |
| Food and Beverage | $399.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $1,060.86 | 2024 | |
| Ucb, INC. | $200.42 | 2024-2025 | Bimzelx, Briviact |
| Mylan Specialty L.P. | $36.12 | 2024 | Yupelri |
| Amgen INC. | $30.41 | 2025 | Evenity, Prolia |
| Grifols USA, LLC | $25.76 | 2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $23.70 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.97 | 2024 | Ofev |
| Glaxosmithkline, LLC. | $19.67 | 2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $14.64 | 2025 | |
| Abbvie INC. | $13.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.77 | 2025 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.